Scope of US Patent 7,214,364 (Aztreonam Lysinate Inhalation) and US Patent Landscape: Claims, Patent Estate Coverage, and Generic/Biosimilar Entry Risks
Executive summary: US Patent 7,214,364 is a composition-of-matter and method-administration patent focused on inhalable aztreonam lysinate as a dry powder (1–5 µm MMAD) and on closely related inhalable regimens, including alpha-aztreonam lysinate, specified gram-negative pathogen targets, and detailed dose, inhalation device, solution pH/saline composition, and impurity/stability specifications. The claim set also ties together device and dosing frequency limits (including dry powder via DPI and aerosolable solution via MDI) with quantitative safety and quality constraints. The main freedom-to-operate risk for a generic or follow-on entrant is that any product falling within the same aztreonam lysinate form (alpha), inhalable particle size, pathogen treatment claims, dose amounts and frequency limits, and the specific solution parameters (saline chloride range, pH) can trigger direct infringement and, depending on proof, induced/contributory theories.
What exactly does US Patent 7,214,364 claim for inhalable aztreonam lysinate?
Core claim concept (claim 1):
- Inhalable composition comprising aztreonam lysinate
- Intended for pulmonary bacterial infections caused by gram-negative bacteria
- Aztreonam lysinate is prepared as inhalable dry powder
- Particle size: mass medium average diameter (MMAD) 1 to 5 µm
- Mechanistic and therapeutic framing is “treatment of pulmonary bacterial infections,” with the “gram-negative bacteria” limitation
Claim 1 is the anchor: it sets the product boundary as an inhalable dry powder of aztreonam lysinate in a specific aerodynamic size window (1–5 µm). Downstream claims then narrow by crystal form, pathogen, dose and administration options, and quality parameters.
Which aztreonam salt/form is protected (alpha-aztreonam lysinate)?
- Claim 2: composition of claim 1 wherein aztreonam lysinate is alpha aztreonam lysinate
- Claim 10: alpha aztreonam lysinate prepared from an alpha aztreonam form
- Claim 11–12: specify impurity and contaminant thresholds and stability
Practical scope implication: the estate is not merely covering “aztreonam lysinate” broadly. A major narrowing axis is polymorph/crystal form (alpha). A product using a different crystalline form (if it exists and is not equivalent in infringement analysis) can be outside at least claims expressly requiring “alpha.” But claim 1 still covers “aztreonam lysinate” generally unless the accused product is clearly outside “prepared as an inhalable dry powder having MMAD 1 to 5 µm” or outside the lysinate form used.
What organisms are named and how far does that restriction go?
- Claim 3: Burkholderia cepacia
- Claim 4: Stenotrophomonas maltophilia
- Claim 5: Alcaligenes xylosoxidans
- Claim 6: multidrug resistant Pseudomonas aeruginosa
Scope effect: these are dependent claims limiting the therapeutic use by specific gram-negative organisms. Infringement for these dependents requires the accused product being used for the specified organism(s) within the claim’s therapeutic framing (depending on how the jurisdiction treats use-based claims and evidence of intended use).
How narrow are the particle size and inhalable delivery parameters?
Particle size limitation (claim 1):
- MMAD from about 1 to about 5 µm
This is a strict product-definition hook for dry powder inhalers. Many formulation efforts target respirable fractions (often 1–5 µm), so this limitation is commercially relevant and likely overlaps with typical inhalation product design.
Dose and daily regimen boundaries
- Claim 7: composition comprises 1 to 250 mg aztreonam lysinate; may be administered as:
- inhalable dry powder by a dry powder inhaler, or
- aerosolable solution by a metered dose inhaler (MDI) (the claim explicitly introduces both delivery routes)
- Claim 8: composition comprises 10 to 100 (units not fully shown in the prompt; the claim text truncates/omits units context but is clearly a dependent quantitative limitation)
- Claim 9: 75 mg aztreonam lysinate; administered twice or three times a day
- Claim 16 (method): administration one to twelve times per day, with total dose cap if >2/day:
- if delivered more than twice daily, total aztreonam lysinate not higher than 750 mg/day
Scope implication: even if an entrant matches particle size and form, dose scheduling is another infringement vector. If the label regimen or off-label use matches the claim’s frequency and daily cap (claim 16), the method claim can be implicated even if the composition is arguably outside a dependent composition claim.
What formulation-quality claims could block generics or reformulations?
The patent includes explicit quality/impurity/stability constraints attached to the alpha form.
Impurity and stability (claim 11–12)
- Claim 11: alpha aztreonam lysinate has:
- impurity lower than 1%
- stability for at least two years
- Claim 12:
- less than 100 ppm residual alcohol
- initial contaminant levels from alpha aztreonam lysinate are less than 1%
Scope implication: these are stringent product-characterization limits. A generic maker can attempt to avoid direct infringement by producing a different solid form or using different acceptable impurity profiles, but within-scope may still occur if test results show the product meets these thresholds. In litigation, these become “satisfy or not” analytical issues.
Solution/aerosolable formulation parameters (claims 13–15)
Even though the umbrella anchor is a dry powder, the claim set also covers an aerosolable solution administered via MDI.
- Claim 13: solution in saline:
- saline volume 1 to 5 mL
- chloride 0.09% to 0.9% w/v (or equivalent amount of bromine or iodine)
- aerosolable
- pH 4.2 to 7.5
- Claim 14: sodium chloride:
- 0.1% to 0.45% w/v
- pH 5.5 to 7
- Claim 15: aztreonam lysinate concentration:
Scope implication: these claims create a formulation space that may be very difficult to “design around” while still delivering aztreonam lysinate via inhalation using conventional saline buffers. If an accused MDI/aerosol solution falls within these ranges, dependent infringement is plausible.
How do the method claims work, and where does delivery device matter?
- Claim 16 (method for administering aztreonam lysinate):
- administration of the composition of claim 7
- via dry powder inhaler or metered dose inhaler
- frequency: one to twelve times a day
- total daily dose cap if >2/day: ≤ 750 mg/day
Device linkage: Claim 16 explicitly ties infringement to both DPI and MDI administration routes. So a competitor cannot easily avoid infringement by switching device type if the product is still within the composition claim.
Regimen linkage: method claims are often litigated through prescribing/labeling evidence and real-world use. The frequency and daily cap can align with clinical regimens and thus strengthen the evidentiary basis.
What is the likely “infringement-relevant” claim hierarchy?
- Claim 1 (broadest anchor): inhalable dry powder aztreonam lysinate, MMAD 1–5 µm, gram-negative pulmonary infections
- Claim 2 (form restriction): alpha aztreonam lysinate
- Claim 3–6 (organism restriction): specific gram-negative targets
- Claim 7–9 (dose and device route): 1–250 mg; DPI or MDI; specific 75 mg twice/three times daily
- Claim 10–12 (quality/impurity/stability): alpha form + impurity/residual alcohol/contaminants/stability
- Claim 13–15 (solution parameters): saline volume/chloride/pH and 75 mg/mL concentration
- Claim 16 (administration method): frequency + daily cap + device routes
Design-around pathways that are suggested by the claim set itself:
- Shift outside MMAD 1–5 µm for dry powder
- Use a non-alpha crystalline form and avoid equivalence arguments tied to “alpha” preparations
- Avoid the specified dose and frequency regimes and daily cap in actual use patterns
- For MDI/aerosol formulations, avoid the specified chloride range and pH windows and the ~75 mg/mL concentration (while still achieving inhalation performance)
- Avoid intended use for the specific named organisms in dependent use claims (though primary claim 1 still covers “gram-negative bacteria” generally)
Patent landscape analysis: how US 7,214,364 is likely positioned within aztreonam lysinate inhalation IP
Important constraint: You provided only the claim text for US 7,214,364. A complete, data-accurate landscape requires the patent bibliographic data (publication number, filing date, assignee, and prosecution history) and/or the Orange Book/NDA listing plus citation graph. Without those, an accurate mapping of:
- forward citations and family members,
- continuations/divisionals,
- related patents on particle engineering, alpha polymorphs, impurity profiles, and aerosol saline formulations, and
- litigation/Paragraph IV status
cannot be produced without risking inaccuracy.
Accordingly, the landscape analysis below is limited to claim-driven issue mapping for what adjacent patents typically exist in this technology space and how US 7,214,364 likely overlaps them. This is structural, not bibliographic.
Adjacent IP clusters that typically co-exist in inhaled beta-lactam salt/polymorph technology
- Polymorph/crystal form and solid-state process patents
- Claim 2/10/11/12 indicate alpha form and manufacturing/impurity control.
- Particle engineering and DPI performance patents
- Claim 1’s 1–5 µm MMAD is a formulation and characterization hook.
- Inhalation regimen and dosing-frequency patents
- Claim 16 includes wide frequency but a total daily cap.
- Aerosol/solution formulation and pH/saline composition patents
- Claim 13–15 indicate specific chloride and pH ranges and a target concentration.
- Method-of-use patents for specific gram-negative pulmonary pathogens
- Claim 3–6 are organism-specific.
Where does the “alpha” requirement increase legal leverage?
Polymorph-specific claims often create a stronger barrier to generic design-around because the competitor must either:
- prove a different polymorph and avoid equivalence, and/or
- rework analytics to show non-infringement by impurity/residual alcohol/stability metrics.
The presence of impurity and residual alcohol thresholds (claim 11–12) increases the evidence burden and can shift the dispute toward analytical testing methodology and batch comparability.
Where does the particle-size window create practical overlap?
MMAD 1–5 µm is a common target for inhaled therapies. If multiple entrants aim for respirable deposition, a broad number of candidate formulations can land inside the claim window unless they intentionally push outside it.
How do dual-route coverage (DPI and MDI) change competitive risk?
Many generic strategies pick a single device route. Claim 7 and claim 16 cover both:
- DPI (dry powder) and
- MDI (aerosolable solution)
So an entrant cannot avoid risk simply by choosing one device route if the underlying formulation and regimen still satisfy claim limitations.
Key “scope hotspots” for product development and litigation
Hotspot 1: MMAD 1–5 µm
- Testing disputes can turn on the measurement method (cascade impactor configuration, humidity control, etc.), but the claim is still tied to MMAD.
Hotspot 2: alpha-aztreonam lysinate and impurity/residual alcohol
- If alpha form is used, quality thresholds become direct infringement triggers.
- If a competitor uses a different form, equivalence and “prepared from” alpha form language can matter.
Hotspot 3: solution saline chloride and pH
- Many inhalation formulations use buffered saline.
- Claim 13–15 narrow acceptable chloride and pH ranges and anchor ~75 mg/mL concentration.
Hotspot 4: dosing frequency and the 750 mg/day cap
- If the labeled regimen, physician-directed practice, or clinical evidence supports dosing inside claim 16, method claim exposure rises.
Key Takeaways
- US 7,214,364 protects inhalable aztreonam lysinate as dry powder with MMAD 1–5 µm for gram-negative pulmonary bacterial infections (claim 1).
- A major narrowing axis is alpha-aztreonam lysinate (claims 2, 10–12), reinforced by impurity (<1%), stability (≥2 years), and residual alcohol (<100 ppm) constraints.
- The patent also covers dependent organism-specific claims for Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa (claims 3–6).
- Dose and regimen limits include 1–250 mg composition amounts (claim 7), a specific 75 mg regimen twice or three times daily (claim 9), and a method frequency framework with a ≤750 mg/day cap when dosing exceeds twice daily (claim 16).
- The claim set extends beyond DPI to MDI/aerosolable saline solutions with specified chloride, pH, saline volume, and ~75 mg/mL concentration (claims 13–15).
- Competitive design-around will be most constrained by the combination of (i) particle size, (ii) alpha form and quality thresholds, (iii) the DPI/MDI dual-route claim coverage, and (iv) regimen frequency/daily cap.
FAQs
1. Can a competitor avoid infringement by switching from DPI to MDI?
Not if the accused product still satisfies the dependent composition and method limitations that explicitly cover both DPI and MDI routes (claims 7 and 16).
2. Does the patent require treatment of specific pathogens to infringe?
Claim 1 requires only gram-negative pulmonary bacterial infections. Specific organisms (claims 3–6) are dependent limitations.
3. What is the single most important product-definition parameter in the patent?
For the core composition claim, the inhalable dry powder MMAD of 1–5 µm.
4. Do impurity and residual alcohol limits matter if the competitor uses alpha-aztreonam lysinate?
Yes. Claims 11–12 add direct quantitative thresholds for impurity, residual alcohol, initial contaminants, and stability.
5. Is there a daily dose ceiling in the method claim?
Yes. If administered more than twice daily, total aztreonam lysinate must not exceed 750 mg/day under claim 16.
References (APA)
- User-provided claim text for US Patent 7,214,364 (aztreonam lysinate inhalable composition and method claims).
